ESMO 2025 preview – Sanofi’s lead shot gets a boost
The group toplines a phase 2 win with Alphamedix.
The group toplines a phase 2 win with Alphamedix.
The French group takes a shot at Perspective with its second bet on Orano Med.
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.